Inhaled insulin for type 2 diabetes
Record ID 32006001576
English
Authors' objectives:
Patients with type 2 diabetes require exogenous insulin when diet and exercise or oral hypoglycemic agents (OHAs) no longer provide adequate glycemic control. Inadequate glycemic control can lead to serious metabolic and long-term vascular complications. Conventional insulin therapy involves multiple, daily, subcutaneous injections. Recently, oral inhalation systems have been developed that deliver short-acting insulin, with the goal of providing a more tolerable delivery system and encouraging earlier acceptance of insulin therapy in patients with type 2 diabetes.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=4924
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Administration, Inhalation
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Insulin
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.